Adalimumab - Biologic Drug Details

Summary for Adalimumab

Tradenames:	1
High Confidence Patents:	63
Applicants:	11
BLAs:	11
Suppliers: see list	17
Recent Clinical Trials:	See clinical trials for Adalimumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for Adalimumab

Recent Clinical Trials for Adalimumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
University Medical Center Groningen	PHASE1
University of California, San Francisco	PHASE4

See all Adalimumab clinical trials

Recent Litigation for Adalimumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
ModernaTX, Inc. v. Pfizer Inc.	2022-08-26
Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.	2022-07-15
Galderma Laboratories L.P. v. Lupin Inc.	2021-12-03

See all Adalimumab litigation

PTAB Litigation

Petitioner	Date
	2017-12-20
Sandoz Inc.	2017-11-06
Sandoz Inc.	2017-10-02

See all Adalimumab litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for Adalimumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 28, 2017	8,911,737	2022-05-06
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,992,926	2022-05-06
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	9,085,620	2023-07-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	9,181,337	2033-03-14
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	9,284,371	2027-09-13
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	9,359,434	2033-03-14

2) High Certainty: US Patents for Adalimumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,493,152	2035-05-15	DrugPatentWatch analysis and company disclosures
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11,167,030	2040-12-29	DrugPatentWatch analysis and company disclosures
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11,191,834	2040-12-29	DrugPatentWatch analysis and company disclosures
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11,229,702	2036-10-28	DrugPatentWatch analysis and company disclosures
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	8,420,081	2028-11-28	DrugPatentWatch analysis and company disclosures
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	8,663,945	2031-11-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for Adalimumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,010,585	2035-06-16	Patent claims search
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,012,654	2033-12-23	Patent claims search
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,016,338	2036-12-20	Patent claims search
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,023,608	2034-03-13	Patent claims search
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,028,940	2037-03-16	Patent claims search
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	10,047,141	2035-01-29	Patent claims search

International Patents for Adalimumab

Country	Patent Number	Estimated Expiration
Mexico	PA05004344
New Zealand	597334
South Korea	20120139851
New Zealand	587754
Poland	376705
Japan	2016155801

Supplementary Protection Certificates for Adalimumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2004C/002	Belgium		PRODUCT NAME: ADALIMUMAB; AUTHORISATION NUMBER AND DATE: 56221 20030902
2004/004	Ireland		PRODUCT NAME: ADALIMUMAB; NAT REGISTRATION NO/DATE: EU/1/03/257/001-006 20030901; FIRST REGISTRATION NO/DATE: CH 56221 20030416
SPC/GB04/002	United Kingdom		PRODUCT NAME: ADALIMUMAB; REGISTERED: CH 56'221 20030416; UK EU/1/03/257/001 20030901; UK EU/1/03/257/002 20030901; UK EU/1/03/257/003 20030901; UK EU/1/03/257/004 20030901; UK EU/1/03/257/005 20030901; UK EU/1/03/257/006 20030901
300143	Netherlands		PRODUCT NAME: ADALIMUMAB; NATIONAL REGISTRATION NO/DATE: EU/1/03/257/001 20030901; FIRST REGISTRATION: CH 56221 20030416
0491001-4	Sweden		PRODUCT NAME: ADALIMUMAB
04C0001	France		PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001 20030901; FIRST REGISTRATION: LI - 56221 20030416

Adalimumab (Humira) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is adalimumab’s market position and how is the category shifting?

Adalimumab (Humira; AbbVie) is the largest commercial TNF-alpha biologic and remains a core platform for autoimmune indications. Its market dynamics are dominated by three forces: (1) biosimilar entry and price compression, (2) patent and regulatory geography, and (3) payer and provider switching behavior.

Key category reality: the US and EU have already moved through the first major wave of anti-TNF biosimilar adoption, and the remaining pressure comes from deeper penetration at the pharmacy benefit manager (PBM) and health-system level rather than from first-time product availability.

Global launch and durability

Adalimumab entered the market in the early 2000s and built peak sales through broad label coverage and strong switching acceptance versus originators in multiple geographies. The financial trajectory since then has been defined less by uptake cycles and more by loss of exclusivity and biosimilar share shift.

Where the market dynamics are most active

• United States: sustained biosimilar penetration after clearance of multiple candidates has driven systematic price deflation and volume share movement away from Humira.
• European Union: country-level tenders and formulary decisions have intensified after multiple biosimilar launches; contracting mechanics often accelerated volume share shifts.
• Rest of world: adoption tends to follow regulatory approval timing and procurement tender schedules, with variability by public payer structures.

How did biosimilars change the revenue curve for Humira?

Biosimilar competition reduced pricing and eroded share, creating a stepwise decline pattern after loss of exclusivity. The market response is consistent with historical biologic biosimilar behavior: initial share loss after entry, then additional losses as PBMs, formularies, and provider groups converge on preferred biosimilar products.

Financial inflection: US patent cliff and accelerated erosion

Humira’s US exclusivity expiration and subsequent biosimilar approvals initiated a multi-year downtrend. AbbVie reported a sharp decline in Humira revenues following the initial biosimilar impact and then continued reductions as competition widened.

Financial inflection: EU geography

EU adoption often occurred via tender and reference-based pricing dynamics, with biosimilar procurement gradually replacing originator stock and maintaining downward pressure on net pricing.

What do consensus financial trends indicate about adalimumab’s trajectory?

Across major markets, the trajectory has followed a predictable pattern:

1. Peak-era stability while exclusivity held
2. Volume and net price erosion after biosimilar entry
3. Stabilization at lower revenue levels once formularies consolidate around preferred biosimilars
4. Ongoing decline or flattening driven by continued competition from additional biosimilars and switching incentives

The net result is that adalimumab is no longer in growth mode in the originator form. Instead, it functions as a declining revenue franchise, with remaining value concentrated in markets and channels that retain originator volume longer.

How large is the financial footprint and what is the trajectory for originator sales?

AbbVie’s segment reporting shows Humira as a major contributor for years and then a shrinking contributor after biosimilar entry. The company’s disclosure ties the decline directly to biosimilar competition and related pricing pressure.

AbbVie reported Humira sales trend (originator)

AbbVie’s financial disclosures for Humira show a decline from the peak sales period to substantially lower revenues after biosimilar uptake.

Metric	Direction since biosimilar entry	Business driver
Humira net revenues	Down	Biosimilar competition and net price erosion (AbbVie disclosures)
Share in key accounts	Down	PBM and formulary switching
Net pricing	Down	Competitive contracting and tender dynamics

(Source: AbbVie investor reports and earnings materials covering Humira sales impact.)

What are the key competitive products and how does their entry affect pricing power?

After biosimilar launches, competition fragments originator pricing into contracted net rates. Once multiple biosimilars are available, payers typically select at least one product as a preferred option, which forces further price compression among non-preferred options.

Observed competitive pattern

• First biosimilar entrants: establish discounted price anchors and quickly attract switching where contracts allow.
• Multiple biosimilars: expand payer choice, strengthen tender leverage, and accelerate net price declines.
• Originator response: limited because clinical equivalence is established; originator leverage often becomes supply-chain and contracting rather than differentiation.

What market forces control adalimumab’s near-term economics?

Near-term adalimumab economics are controlled by payer contracting and the operational mechanics of biosimilar switching.

Core drivers

• Formulary design and step therapy: once biosimilars are designated preferred, originator volume drops quickly.
• PBM rebates and bid structure: preferred biosimilar bids pull down effective net pricing.
• Tender schedules (EU and public procurement): procurement cycles create stepwise shifts rather than linear decline.
• Copay and patient support policies: switching is influenced by out-of-pocket cost and benefit design.
• Clinical switching guidelines: in practice, provider comfort and local protocols govern timing of transitions.

How does the broader portfolio alter the financial trajectory for AbbVie?

As Humira declines, AbbVie’s overall revenue trajectory depends on migration to next-generation therapies. Adalimumab’s originator franchise can offset risk only when managed alongside:

• Next-line immunology launches
• Expanded indications where biosimilar pressure does not remove all value immediately
• Manufacturing and supply optimization to protect margin in remaining originator volume

The originator becomes a cash-flow contributor during the decline but no longer acts as a growth engine.

What are the key corporate financial implications for investors and operators?

From a business perspective, adalimumab’s trajectory impacts three decisions: pricing discipline, channel management, and R&D capital allocation.

Investment and operating implications

• Revenue visibility shifts to contract management: a large portion of performance becomes dependent on the timing of tender cycles and PBM renewals.
• Margin protection is less about price leadership and more about mix: originator volume declines; retained volume tends to be in specific accounts with longer contract durations.
• R&D capital prioritizes pipeline substitution: as Humira revenue falls, replacement strategies become critical to maintain immunology franchise value.

What regulatory and commercial milestones matter most?

Adalimumab’s commercial course is tied to exclusivity, biosimilar approval, and label maintenance. The most material milestones occur when:

• US and EU exclusivity ends, enabling biosimilars to enter
• Additional biosimilars secure approval and coverage
• Formularies and tenders change preferred status

These milestones drive the speed and magnitude of financial erosion.

How does the payer switch timeline typically translate into financial outcomes?

Payer switching does not occur instantly across all lines of business. The pattern is:

• Wholesale buy-in by large payers after biosimilar availability
• Gradual uptake in smaller plans and health systems
• Residual originator use sustained by legacy contracts

This creates a multi-year decline rather than a single-year collapse.

What does this mean for the biologic market structure overall?

Adalimumab exemplifies a mature biologic market:

• Multiple biosimilars exist (or have existed) by major geography
• Payer contracting largely determines volume share
• The originator’s differentiation becomes limited relative to price-driven procurement

This structure implies that future financial performance is highly sensitive to competitive bidding and contracting terms rather than to incremental clinical uptake.

---

Key Takeaways

• Adalimumab’s originator revenue trajectory is defined by biosimilar-driven pricing compression and formulary switching after loss of exclusivity in major markets.
• Market share erosion follows contract mechanics (PBMs, hospital formularies, EU tenders), producing multi-year declines rather than immediate step changes.
• Near-term adalimumab economics depend on payer preferred product selection and procurement cycles, not on new uptake-led growth.
• For investors and operators, the financial focus shifts from growth strategy to cash-flow maintenance and pipeline substitution to replace declining originator revenues.

---

FAQs

1) Is adalimumab still the top anti-TNF by revenue today?

It remains one of the largest anti-TNFs historically, but originator revenue has been structurally pressured by biosimilar penetration and net pricing erosion following exclusivity loss.

2) What drives the speed of Humira revenue decline after biosimilar entry?

Payer contracting behavior, including PBM preferred formulary decisions and hospital tender cycles, which translate availability into volume share loss.

3) Why do adalimumab revenues decline over multiple years rather than immediately?

Contracts and procurement cycles delay full switching across accounts, and residual originator volume persists under legacy arrangements.

4) How do additional biosimilars affect net pricing?

Multiple approved products increase payer leverage during bid and tender cycles, typically intensifying net price pressure and accelerating share shifts.

5) What should be watched to model the next adalimumab earnings trend?

PBM formulary changes, preferred biosimilar status updates, and the timing of EU tender/procurement decisions that determine stepwise volume shifts.

---

References

[1] AbbVie. Investors & Financial Reports: Humira-related financial disclosures (earnings releases and annual reports covering Humira sales impact from biosimilar competition). https://www.abbvie.com/investors.html
[2] FDA. Biosimilar Product Information (regulatory pathway and approved biosimilars for biologics). https://www.fda.gov/drugs/biosimilars
[3] EMA. Biosimilar medicines overview and scientific guidance (EU regulatory and assessment framework). https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines